EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost‐Effectiveness Analysis of Patient Self‐Management of Warfarin Among Patients With Non‐Valvular Atrial Fibrillation

Warittakorn Kategeaw iD, Daniel M Witt iD, Jordan B King, Daniel C Malone iD, Nathorn Chaiyakunapruk iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026-06 · 46 (6)

DOI: 10.1002/phar.70154 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, online erschienen am 14.05.2026. Verfasst von Warittakorn Kategeaw und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Warfarin, Anticoagulants, Self-Management. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AHRQ HHS, Agency for Healthcare Research and Quality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patient self‐management (PSM) is a warfarin management strategy that allows patients to independently adjust their doses. PSM significantly reduces thrombosis events and has been widely implemented internationally. However, adoption of PSM is limited in the United States. This study estimated the cost‐effectiveness of PSM compared with available strategies, including anticoagulation management services (AMS) and usual care (UC) for patients with non‐valvular atrial fibrillation (NVAF) aged 70 years and older in the United States.

Methods

A cost‐effectiveness analysis was performed to estimate lifetime costs and outcomes of PSM compared with AMS and UC employing a Markov model. The model simulated a 70‐year‐old with NVAF over the patient's lifetime from modified societal and payer perspectives. Transition probabilities were derived from annual event rates reported in the ARISTOTLE trial. Comparative efficacy and safety among the interventions were obtained from a network meta‐analysis. Costs, presented in 2024 US dollars (USD), and utility data were obtained from data sources in the United States. A discount rate of 3% was applied for future costs and outcomes. One‐way sensitivity analysis and probabilistic sensitivity analysis were performed to assess the robustness of the findings.

Results

The lifetime costs from the modified societal perspective were $137,509 USD for UC, $129,216 USD for AMS, and $76,515 USD for PSM. Discounted quality‐adjusted life years (QALYs) were estimated to be 8.27 for UC, 8.30 for AMS, and 8.47 for PSM. Additionally, PSM substantially reduced stroke incidence compared with AMS and UC, contributing to lower costs and greater QALYs. Probabilistic sensitivity analysis showed that PSM appeared to be the most cost‐effective at any willingness‐to‐pay threshold.

Conclusions

PSM is the most cost‐effective strategy for managing warfarin in the target population at any willingness‐to‐pay threshold. Implementation of PSM in the US health care setting should be considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationWarfarinAnticoagulantsSelf-ManagementHumansCost-Effectiveness AnalysisCost-Benefit AnalysisAgedUnited StatesMarkov ChainsStrokeQuality-Adjusted Life YearsMale

Stichwörter der Autor:innen

anticoagulationcost‐effectivenessnon‐valvular atrial fibrillationself‐managementwarfarin

Substanzen

WarfarinAnticoagulants

Autor:innen und Institutionen

  • Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA.
  • Department of Population Health Sciences, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA.
  • Institute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado, USA.
  • IDEAS Center, Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, Utah, USA.

ORCID-Profile: Warittakorn Kategeaw, Daniel M Witt, Daniel C Malone, Nathorn Chaiyakunapruk

Förderung

  • AHRQ HHS
  • Agency for Healthcare Research and Quality

Zitieren

APA

Kategeaw, W., Witt, D. M., King, J. B., Malone, D. C., & Chaiyakunapruk, N. (2026). Cost‐Effectiveness Analysis of Patient Self‐Management of Warfarin Among Patients With Non‐Valvular Atrial Fibrillation. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 46(6). https://doi.org/10.1002/phar.70154

Vancouver

Kategeaw W, Witt DM, King JB, Malone DC, Chaiyakunapruk N. Cost‐Effectiveness Analysis of Patient Self‐Management of Warfarin Among Patients With Non‐Valvular Atrial Fibrillation. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026;46(6). doi:10.1002/phar.70154

BibTeX
@article{Kategeaw2026,
  author = {Kategeaw, Warittakorn and Witt, Daniel M and King, Jordan B and Malone, Daniel C and Chaiyakunapruk, Nathorn},
  title = {Cost‐Effectiveness Analysis of Patient Self‐Management of Warfarin Among Patients With Non‐Valvular Atrial Fibrillation},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2026},
  volume = {46},
  number = {6},
  doi = {10.1002/phar.70154}
}
Kostenlos starten →